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Abstract
Hepatitis C virus (HCV) is a major public health problem in the Middle East and North Africa (MENA) region with an estimate of over
15 million chronically infected patients. However, molecular characterization of circulating genotypes in the MENA region remains
elusive. Here, we performed a comparative phylogenomic analysis of so-far available E1 gene sequences (937), originating from eight
countries in the MENA region. All HCV E1 protein sequences present in NCBI from the MENA region were retrieved and cataloged per
year and country of origin. Phylogenetic analysis revealed a maximum diversity of genotypes and subtypes in South Arabia [G-1 (1a,
1b, 1g), G-2 (2a, 2c), G-3 (3a) and G-4 (4a, 4d, 4n, 4o, 4r, 4s)] followed by Egypt [G-1 (1b, 1g) and G-4 (4a, 4l, 4n, 4m, 4u)], Iran [G-1 (1b) and G-3
(3a) G-6 (6a)], Tunisia [G-1 (1b) and G-2 (2a, 2b, 2c)], Algeria [G-1 (1i), 4(4f), Pakistan [G-1 (1a), G-3(3a, 3b)], Afghanistan [G-1 (1a), GT-3 (3a)],
and 5(5a), and Yemen [G-4 (4r)]. The calculated evolution rate of retrieved sequences was 1.601× 10-3 substitutions/site/year and the
mean nucleotide diversity rate was 0.2684 (P < 0.001). The ratio of synonymous to non-synonymous (mean dN/dS) substitutions
was higher in genotypes 2 and 4 compared to the genotypes 1 and 3. A higher degree of nucleotide identity in E1 gene was found
between subtypes 1a and 1b, between 2c and 2g, and between 4a, 4d, and 4o. Comparative residue analysis of E1 protein epitope se-
quences of previously reported H111, A4, and A6 monoclonal antibodies showed relatively poor and genotype-specific conservancy.
Perhaps, none of the reported epitope sequences had immunogenicity score higher than 0.4 (A minimum threshold for vaccine
sequence prediction). Furthermore, these epitope sequences were heavily glycosylated at amino acid 196, 209, and 234 sites in all
GTs. In conclusion, a high genetic variability in E1 protein coupled with increased glycosylation may deduce heterogeneity and sub-
sequent escape from vaccine-generated immune response, thereby ascertaining necessary interventions for disease management
and control.
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1. Context
Hepatitis C virus (HCV) is a pathogen of global health
significance. Africa and Asia are the most affected regions
with the highest prevalence rates and over 15 million indi-
viduals are infected with chronic HCV in the Middle East
and North Africa (MENA) region alone (1). About 80% of the
acute hepatitis C cases progress to chronic infection and
10% - 20% of them develop complications characterized by
chronic inflammation, liver cirrhosis, and hepatocellular
carcinoma (2). The virus exhibits high replicative activity
leading to high genetic diversity and can be classified into
seven genotypes, and more than 67 subtypes (3). In the
MENA region, country-specific genotype distribution is cal-
culated previously by Mahmud, Al-Kanaani (1). The authors
report that pooled mean proportion of genotype 1 is higher
in Algeria, Morocco, Iran, Tunisia, and Bahrain, whereas
genotype 3 mainly prevails in Pakistan and Afghanistan.
Egypt, Saudi Arabia, Jordan, and Palestine are predomi-
nantly occupied by genotype 4.
The virus has 9.6 kb long RNA genome that encodes
three structural proteins (core, E1, and E2) and seven non-
structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and
NS5B). The maximal variability is observed in genes encod-
ing the envelope glycoproteins E1 and E2 (4). The struc-
tural envelope glycoproteins (E1 and E2) facilitate virus en-
try into the host cell and escape from the host immune sys-
tem using different adaptive mechanisms. These glycopro-
teins bind surface receptors on hepatic cells and partici-
pate in endocytosis and virion formation (5). Envelope pro-
tein E2 has been extensively characterized and was initially
assumed responsible for virus binding and fusion with the
host cells (6). Contrary to this suggestion, recent work pro-
poses that E1 alone or in combination with E2 may be in-
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volved in virus fusion (7). A conserved hydrophobic mo-
tif (CSALYVGDLC, residues 272-281) in E1 gene is believed to
be associated with virion fusion process (8). The disulfide
and covalent bonds between E1 and E2 proteins make E1/E2
heterodimer, a type I transmembrane protein that releases
individual E1 and E2 from the polyprotein by signal pepti-
dase cleavages (9). After the cleavage, E1 protein targets the
endoplasmic reticulum lumen where it is modified by N-
glycosylation. All HCV genotypes carry 4 to 5 potential N-
glycosylation sites on E1 protein, playing important roles
in protein folding, virion morphogenesis, and immune es-
cape (10, 11).
The high glycosylation rate on E1 protein significantly
limits the immunogenicity of HCV and restrict the bind-
ing of antibodies to their epitopes. Chronic infections arise
through high mutation rates in the envelope proteins and
formation of glycosylation-associated cellular aggregates
and viral quasispecies that help virus escape from the im-
mune system (12). Recently, the proposed HCV E1 crys-
tal structure and in vitro analysis of N-terminal domain
(192-270) revealed a conserved protein domain organiza-
tion, encompassing N-glycosylation sites, antigenic sites
defined by neutralizing monoclonal antibodies, and direct
drug binding sites (13). Limited data are available on E1
polymorphism, mutagenesis, and immunogenicity anal-
ysis of a large population cohort using in silico bioinfor-
matics tools. Here, we performed these analyses on 937 se-
quences of HCV E1 protein that originate from the MENA
region. Such knowledge is important not only to eluci-
date ongoing evolution in HCV but also to facilitate nec-
essary interventions for effective control of HCV through
novel vaccine and antiviral drug approaches. Although
countries in the MENA region have the highest HCV preva-
lence rate, relatively little attention has been paid on HCV
genome characterization in this region. In this study, the E1
protein is chosen because of the availability of sequences
from the MENA region in the Gene Bank database and also
because it has been less explored at the molecular level.
2. Materials and Methods
2.1. E1 Sequences
HCV E1 gene sequences obtained from the MENA region
were downloaded from GenBank database maintained by
NCBI (14). A search was performed using the combination
of the following search queries; “Hepatitis C Virus”, “HCV”,
“envelope protein” “E1 protein”, and “country name”. The
search produced 1,199 complete or partial E1 sequences for
Saudi Arabia (446), Egypt (428), Tunisia (119), Iran (57), Pak-
istan (112), Afghanistan (29), Yemen (5), and Algeria (3). All
sequences were aligned against the HCV genotype 1a refer-
ence gene H77 (coordinates 915 - 1491) using MAFFT v7.310
(15) and the alignments were clipped to codon positions
192 - 300 of E1 protein, corresponding to nucleotides 915
- 1240 on H77 reference genome. Partial sequences that
had sequence length less than 300 bp or which lacked
N-terminal domain were removed, resulting in 937 se-
quences for further analysis. A systematic analysis of these
sequences was performed using different bioinformatics
tools (Figure 1).
2.2. Sequence Alignment and Phylogenetic Analysis
For phylogenetic analysis, we randomly selected only
278 sequences, which represented all genotypes, years,
and country of isolation. Phylogenetic tree was con-
structed with MEGA® V. 7.0 software (16) using distance-
based neighbor-joining (1,000 replication bootstrap val-
ues). Reference genotype sequences were obtained from
https://hcv.lanl.gov database to construct phylogenetic
tree. All assembled sequences were further pairwise
aligned with genotype-specific reference sequences using
multiple sequence aligned methods in MAFFT tool for E1
nucleotide mutations and amino acid substitution analy-
sis. BioEdit® V. 5.0.6 (17) software was used for nucleotide
mutations identification and comparative residue analysis
of all the sequences.
2.3. Evolution Rate and Site-Specific Selection Pressure
HCV E1 gene evolution rate was estimated using the
Bayesian Markov Chain Monte Carlo (MCMC) algorithm
implemented in the BEAST V. 1.8.4 software (18). Virus iso-
lation dates were used for calibration of the strict molecu-
lar clock in HKY substitution model. The XML file was gen-
erated in BEAUTi program using gamma parameter of site
heterogeneity at 200 million chain-length, echoed every
1,000 states. The estimated effective sampling sizes (ESSs
≥ 200) were used to evaluate sampling convergence of
MCMC method. Sampling prior and mean clock rate were
estimated in Tracer software V. 1.7. To elucidate patterns of
adaptive evolution in E1 protein, single-likelihood ances-
tor counting (SLAC) model in web-based suite-Datamonkey
was used. Site-specific selection pressures were analyzed
for synonymous (dS) to non-synonymous (dN) ratio of nu-
cleotide substitutions per site (19). A codon position with
dN/dS value more than 1 at P value 0.05 was considered pos-
itively selected sites. The nucleotide diversity was analyzed
for polymorphism, and average numbers of pairwise nu-
cleotide differences were determined using DnaSP V. 6.12.01
(20) and Tajima’s D test of neutrality.
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Figure 1. Flowchart of bioinformatics analysis performed on HCV E1 protein. Blue boxes show the work performed and green ovals show the software used.
2.4. Comparative Residue Analysis
Residue diversity and/or conservancy at each amino
acid site were analyzed through online WebLogo (21) pro-
gram. Pairwise analysis of the sequence identity was
performed by bootstrap value 1,000 using MEGA 7 (16).
Residue analysis of key motifs recognized as monoclonal
antibody epitope sites was performed for all genotypes.
Epitope sequences were compared with consensus refer-
ences. Furthermore, residue conservancy of these motifs
was assessed using epitope conservancy analysis program
implemented in the immune epitope database and anal-
ysis resource (IEDB) (22). The program calculated epitope
conservancy as a percentage of the number of polymor-
phic sites over the epitope length. The epitope immuno-
genicity was assessed against HLA class1- alleles using IEDB
epitope analysis tool (23). Finally, a literature review was
conducted to collect available information on amino acid
mutations that may affect the efficacy of direct-acting an-
tiviral drugs targeting E1 protein, which concluded follow-
ing seven residue sites (T213A, W239, I262A, D263-, Q289H,
M267V, F291I, Y297H) (7, 24, 25). Amino acid substitutions at
these specific sites were compared between different geno-
types and reported in a graph as the percentage (Figure 2).
2.5. Prediction of Glycosylation Sites
NetNglyc online tool was used to predict N-linked gly-
cosylation (26). The default settings were used to predict
N-X-T/S sequons. Only scores crossing the default thresh-
old of 0.5 and jury agreement 9/9 were considered positive
for potential glycosylation sites.
3. Results
3.1. Phylogenetic and Evolutionary Analysis
The phylogenetic analysis of HCV E1 gene revealed a dis-
tinct and genotype-specific distribution pattern. All E1 se-
quences clustered together in distinct clades of their re-
spective genotypes. Most of the retrieved sequences be-
longed to genotype 1, 2, 3, 4, except only one sequence
was related to both 5a and 6a genotypes belonged to Alge-
ria and Iran, respectively. Overall, 19 genotypes (subtypes)
were clustered in the phylogenetic tree as presented in Fig-
ure 3. The phylogenetic analysis revealed the evolutionary
dynamic of E1 protein for diverse distribution of various
genotypes and subtypes of HCV in the MENA region. In this
regard, 4a was the most abundant genotype followed by 3a,
and 2c. The maximum diversity of genotypes and subtypes
was observed in South Arabia [G-1 (1a, 1b, 1g), G-2 (2a, 2c), G-3
(3a) and G-4 (4a, 4d, 4n, 4o, 4r, 4s)] followed by Egypt [G-1
(1b, 1g) and G-4 (4a, 4l, 4n, 4m, 4u)], Iran [G-1 (1b) and G-3
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Figure 2. Percentage nucleotide identity and divergence of HCV E1 protein analyzed using pairwise distance maximum composite likelihood algorithm implemented by
MEGA 7. Nucleotide identity percentage are given in the below diagonal, whereas percent divergence values are presented in the above diagonal.
(3a) G-6 (6a)], Tunisia [G-1 (1b) and G-2 (2a, 2b, 2c)], Algeria
[G-1 (1i), 4(4f), Pakistan [G-1 (1a), G-3(3a, 3b)], Afghanistan [G-
1 (1a), GT-3 (3a)], and 5(5a) and Yemen [G-4 (4r)].
The mean evolution rate of the HCV E1 gene in the
MENA region was 1.601× 10-3 (95% HPD interval 1.122× 10-3,
2.081 × 10-3) substitutions/site/year and sampling mean
prior rate was -2.055× 103. Based on the individual coding
gene sequences, the average nucleotide diversity in the E1
gene was 0.268. On average, 454 (max: 956 for 4a genotype
and min: 36 for 4l genotype) mutation sites were observed
in different genotypes with average Tajima’s D test value =
-1.067 (Table 1) (27). Taken together, HCV E1 gene is consid-
ered under positive selection since all Tajima’s D values are
negative for all genotypes (P > 0.10). Datamonkey analysis
of coding DNA sequence (CDS) for dN/dS is summarized in
Tables 2 and 3. Most of the E1 CDS had SLAC model-based
mean dN/dS ratio less than 1 (P < 0.05). The highest dN/dS
ratio was observed in 4a, and 4d genotypes followed by 2a,
4u, 1b, and 2c. Furthermore, 4a genotype showed the high-
est positive selection site followed by 2a, 4d, and 1b geno-
types.
3.2. Comparative Residue Analysis and Sequence Conservancy
Residue diversity and/or conservancy at all amino acid
sites are presented in WebLogo (Figure 4). WebLogo pro-
duced a consensus output sequence from the given input
sequences, wherein, a series of letter stacked over each
other at each polymorphic site. The height of each let-
ter within a stack is proportional to the relative frequency
of the residue at that position in the consensus sequence.
The pairwise analysis of genetic distances shows a higher
degree of nucleotide identity in E1 residue between geno-
types 1a and 1b, between 2c and 2g, and between 4a, 4d, and
4o (Figure 2).
The relative conservancy of the E1 protein epitope se-
quences is presented in Table 4. Genotypes 2a and 4m
had the lowest conservancy among all the genotypes. The
highest conservancy (100%) in H111 monoclonal antibody
epitopes (192YQVRNSSGLYH202) was observed in 1a and 3a
genotypes, while multiple substations were observed in
all other genotypes (Table 5). Similarly, the other two re-
ported epitopes of monoclonal antibodies for A4 (197SSG-
LYHVTNDC207) and A6 (230VREGNASRCW239) antibodies
also showed relatively high sequence conservancy in 1a
compared with the rest of the genotypes. A high degree
of conservancy was observed for 257QLRRHIDLLV266 epi-
tope (this epitope was predicted in the immune epitope
database (28) and has never been reported in the litera-
ture before) among different genotypes. In addition to epi-
tope motifs, a classical 266CXXC229 motif that mediates
the isomerization of disulfide bonds in E1 during virus en-
try (29) is also highly conserved among all genotypes (Ta-
ble 5). The percentage substitution of key residue sites was
determined. Direct drug binding sites that trigger the re-
sistance against direct-acting antivirals were mostly con-
served across genotypes (Figure 5).
3.3. Epitope Conservancy and Immunogenicity Analysis
In silico immune responses to previously recognized
E1 protein epitopes by cytotoxic T lymphocytes (CTLs) was
studied. The epitope immunogenicity predicted on IEDB
analysis tools using MHC class I binding tools showed
a poor immunogenicity score, wherein, all values were
less than 0.4 (threshold for producing strong neutral-
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Figure 3. Comparative phylogenetic analysis of 278 HCV E1 protein sequences divide the sequences into genotype-specific clusters. Each branch header contains NCBI accession
number, country, genotype name, and year of sample isolation. Few branch headers do not contain genotype description because their genotype record was missing at NCBI.
Table 1. Brief Summary of the DnaSP-Derived Polymorphism Analysis for HCV E1 Genea
Genotype Number of Mutations Nucleotide Diversity Standard Deviation Tajima’s D test
1a 393 0.26919 0.06676 -1.28820
1b 513 0.16632 0.02228 -1.73551
1g 257 0.22298 0.03579 -0.70035
2a 804 0.37273 0.04727 -1.26680
2c 752 0.32333 0.03277 -0.96337
2g 68 0.09485 0.01732 -0.58834
3a 321 0.28047 0.09067 -1.50896
4a 956 0.25293 0.01373 -1.13219
4d 612 0.29852 0.03532 -0.90753
4o 225 0.29330 0.09484 -0.8886b
4r 531 0.27851 0.06631 -1.45598
4u 645 0.39274 0.05652 -0.36978
aAnalysis was not done because of less number of sequences required for Tajima’s D test.
bStatistical significance (P < 0.001)
izing antibodies against HCV E1 protein). The percent-
age conservancy and immunogenicity, predicted in IEDB,
are presented in Table 4. The percentage substitution of
key residue sites was determined. Direct drug binding
sites that trigger resistance against direct-acting antivirals
(flunarizine, phenothiazines, pimozide, ferroquine, and
aminoquinoline-derivative molecules) (7, 24, 25) showed
high variability in different genotypes. Therefore, muta-
tions within epitope sequences influence their immuno-
genic potential.
3.4. N-Linked Glycosylation Prediction
HCV E1 is a heavily glycosylated protein that possesses
four to five conserved glycosylation sites (196, 209, 234, 305,
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Table 2. Determination of Synonymous and Non-Synonymous Substitution Rates Using SLAC Method for Genotype 1-3 of Envelope Glycoprotein E1 Gene Circulating in the
MENA Regiona
Genotypes 1a 1b 1g 2a 2c 2g 3a
Mean dN/dS 0.1585 0.2249 0.19876 0.2379 0.2313 0.2133 0.1466
Positive selection sites 0 3 0 4 2 0 0
Codon position 0 28 44 106 0 8 40 73 108 58 73 0 0
dN-dS value 0 1.8525 2.0785 1.4124 0 4.1352 2.8212 3.2354 3.3597 1.1095 1.3131 0 0
P value 0 0.0863 0.0447 0.0995 0 0.0004 0.0129 0.0007 0.0103 0.0781 0.0313 0 0
Negative selection sites 70 63 22 88 64 27 22
a Single-Likelihood Ancestor Counting (SLAC) method implemented by Datamonekey online tool was used to identify dN (non-synonymous) and dS (synonymous) substitutions at P value 0.1. Indeed, SLAC employs a maximum-likelihood
model to infer rates of substations and reports positive selection using posterior probabilities. dN/dS > indicate a positive selection, while < 1 indicate a negative selection site. Analysis was only performed on the genotypes that have
≥ 3 sequences.
Table 3. Determination of Synonymous and Non-Synonymous Substitution Rates Using SLAC Method for Genotype 4 of Envelope Glycoprotein E1 Gene Circulating in the MENA
Regiona
Genotypes 4a 4d 4o 4r 4u
Mean dN/dS 0.1997 0.1669 0.2588 0.1672 0.1314
Positive selection sites 5 4 0 0 2
Codon position 12 41 44 57 65 12 41 44 86 0 0 58 60
dN-dS value 26.075 77.061 58.897 18.0157 16.8035 8.3964 16.5213 21.0521 4.4983 0 0 2.9202 3.4037
P value 0.0012 3.9927e-10 1.758e-08 0.00016 0.0243 0.0093 0.0044 0.0005 0.0833 0 0 0.0814 0.04218
Negative selection sites 111 79 3 23 41
a Single-Likelihood Ancestor Counting (SLAC) method implemented by Datamonekey online tool was used to identify dN (non-synonymous) and dS (synonymous) substitutions at P value 0.1. Indeed, SLAC employs a maximum-likelihood
model to infer rates of substations and reports positive selection using posterior probabilities. dN/dS > indicate a positive selection, while < 1 indicate a negative selection site. Analysis was only performed on the genotypes that have
≥ 3 sequences.
Figure 4. Residue analysis of HCV E1 protein. Constructing multiple sequence alignments, the diversity and/or conserveness of residues at each position were analyzed by
WebLogo 3.1 (21). Vertical rectangles highlight the epitopes regions. Owing to software limitation, those genotypes (3b, 4l, 4m, 4n, 4g) that had less than 3 sequences were
excluded.
and 325) in all genotypes. We used NetNglyc 1.0 webserver
to predict N-glycosylation on the HCV E1 protein sequences
originating from the MENA region. Regardless of E1 se-
quence origin or genotype, all sequences were heavily gly-
cosylated. Since our sequences were 192-300 AA long, we
could only analyze the first three glycosylation sites (196,
6 Hepat Mon. 2019; 19(8):e92437.
Sohail MU et al.
Figure 5. Residue analysis at direct drug binding sites *T213A, *W239, #I262A, #D263-, #Q289H, #M267V, #F291I, #Y297H. Mutation on these residue sites develop resistance
against direct-acting antiviral drugs (flunarizine, phenothiazines, pimozide, ferroquine, and aminoquinoline-derivative molecules). The results are stated as percentage
changes on the individual residue site. *Residue mutations associated with virus entry cycle (7). #Residue mutations associated with drug resistance (7, 24, 25).
209, and 234) in all genotypes (Table 6). Owing to uneven
genotype or country-specific sample size, no appropriate
statistical model could be applied.
4. Discussion
Hepatitis C virus (HCV) is a major public health prob-
lem around the globe with more than 2.5% (177.5 million
adults) of the world population infected with this disease
(2). Asia (2.8%) and Africa (2.9%) are the most infected re-
gions where disease prevalence rates are the highest (2).
Globally, 170 million individuals are chronically inflicted of
which 15 million people belong to the MENA region (30).
Compared to the high HCV prevalence rate in the MENA
region, very few complete genome sequences are avail-
able from this region. Further, the molecular characteri-
zation of circulating strains in this region is also limited.
Generally, HCV genotyping is performed by sequencing 5’-
untranslated region, hypervariable region in the envelope
protein, or by NS5 protein (31). In the present study, we
analyzed 937 HCV E1 partial sequences because of E1 func-
tional significance and relative higher E1 sequences avail-
ability, belonging to different countries in the MENA re-
gion. This is the first of its kind study to perform polymor-
phism, adaptive mutations, evolution frequencies and dy-
namics, and their possible impact on virus immunogenic-
ity.
Genotype 4 tends to be the most abundant circulating
genotype in Saudi Arabia and Egypt, with more than half
of the sequences belonging to subtype 4a. Although geno-
type 1a and 3a are the most abundantly present worldwide
(2); however, only few E1 sequences for these genotypes are
available in NCBI nucleotide repository for MENA region.
Based upon available E1 protein sequences, phylogenetic
analysis revealed the highest diversity in genotype 4, clus-
tering it in several subtypes (4a, 4d, 4f, 4m, 4n, 4o, 4r, 4s,
and 4u). The mean evolution rate of E1 protein was 1.601
× 10-3 substitutions/site/year, which is comparable to pre-
vious estimates (32, 33). Phylogenetic and evolution rates
analysis of E1 protein reported previously from China indi-
cated that E1 protein is under positive selection (32). Sim-
ilarly, we observed here positive selection for E1 protein
with an average nucleotide diversity of 0.268 and Tajima’s
value -1.067.
The positive selection sites were randomly located on
the entire N-terminal domain (NTD) of 4a, 4d, 2a, 1b, 4u,
and 2c genotypes. The NTD is thought to be exposed on the
protein surface and, therefore, may act as a target for host
antibody responses (33). E1 protein is known to contain
several monoclonal antibody epitopes on NTD with po-
tent neutralization effect (34-36). In the present sequences,
high residue divergence and poor immunogenicity score
prove the concept of immune-driven evolution in these
epitope sites (37). Both HCV genotypes and host genet-
ics may determine epitope immunogenicity. Keck, Sung
(35) reported that H111 antibody epitopes (192YQVRNSSG-
LYH202) is highly conserved in 1a, 1b, 2b, and 3a genotypes
and blocks HCV virion attachment to the host cells. Con-
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Table 6. N-Glycosylation at Different Amino Acid Sites in the Envelop Glycoprotein E1 Circulating in the MENA Regiona
Genotype
AA Site (Percentage per Site)b
Saudi Arabia Egypt Iran Tunisia Yemen Afghanistan Pakistan Algeria
Nc 196 209 234 N 196 209 234 N 196 209 234 N 196 209 234 N 196 209 234 N 196 209 234 N 196 209 234 196 209 234
1a 11 0 100 9 2 0 100 0 20 0 95 0 0 0 5 50 2 100 0
1b 40 78 78 5 1 100 100 0 5 40 60 0 30 97 90 30 0 0 0 0
1g 2 100 100 100 7 71 86 43 0 0 0 0 0 0
1i 0 0 0 0 0 0 1 0
3a 7 14 57 0 0 12 0 33 8.3 0 0 22 5 36 38 7.8 18 7.8 0
3b 0 0 0 0 0 0 5 0 60 40 0
4a 272 36 86 4 250 67 80 12 0 0 0 0 0 0
4d 61 4.9 93 26 4 100 75 50 0 0 0 0 0 0
4f 0 0 0 0 0 0 0 1 100 100
4n 3 0 0 67 0 0 0 0 0 0 0
4o 1 100 100 100 3 100 67 0 0 0 0 0 0 0
4r 12 92 33 75 0 0 0 5 100 0 100 0 0 0
4s 2 0 0 0 0 0 0 0
2a 3 0 100 0 0 0 19 16 6.6 43 0 0 0 0
2c 5 100 0 100 0 0 56 0 1.7 52 0 0 0 0
4l 0 3 0 100 33 0 0 0 0 0 0
4m 0 4 50 100 75 0 0 0 0 0 0
4u 0 20 5 85 5 0 0 0 0 0 0
5a 0 0 0 0 0 0 0 1 100
6a 0 0 1 0 0 0 0 0
a The analysis is performed on NetNglyc (26) online tool to predict N-glycosylation at AA site 196, 209, and 234.
b Results are presented in percentage.
c N presents the number of sequences for each genotypes.
trary to these findings, we observed poor conservancy and
immunogenicity of this epitope across HCV genotypes cir-
culating in the MENA region. In fact, these epitope stud-
ies are mostly performed on genotype 1 peptide sequence
that may not align with other genotypes (35). Therefore,
antibodies specific for one genotype may indicate poor
neutralization against other HCV genotypes and compro-
mise the efficiency of the vaccine. Owing to the inconsis-
tent sequence number in all genotypes, no statistical trend
for epitope conservancy and immunogenicity could be ob-
served among genotypes in this study. Surprisingly, all gly-
cosylation sites (n = 783) predicted here fall in these anti-
body epitopes. These glycosylations might mask epitopes
from host antibody responses, and enhance protein fold-
ing, and virion formation (38).
In conclusion, the current study analyzes HCV E1 pro-
tein for genotype distribution and polymorphism in the
MENA region. The study identifies the high genetic diver-
sity and polymorphism in HCV E1 protein, albeit very few
and uneven genotype-specific sequence coverage in the re-
gion. Most of the sequences are reported from Saudi Arabia
and Egypt, which belong to genotype 4. The high variabil-
ity in glycosylation and residue mutation score among dif-
ferent genotypes correlate with the number of sequences
in each genotype; for example, 4a has more than 500 se-
quences but 4m to 4u genotypes have only few sequences
that present fewer glycosylation sequons and mutation
score. However, virus pathogenicity is genotype-specific
since genotype 1 shows a poor response to interferon ther-
apy compared with the genotype 2 or 3. The development
of direct-acting antiviral drugs can significantly improve
responses of interferon therapy. We could not determine
specific markers of pathogenicity in E1 protein due to lim-
ited data available on protein sequences in the literature.
The study elucidates E1 protein polymorphism that tends
to disguise host immune response and resist direct-acting
antivirals. High genetic variability in E1 protein and super-
imposed glycosylation enhance virus polymorphism and
immune escape and make it impossible to develop either
effective vaccine or drug against E1 protein of studied geno-
types and a multitude of subtypes. Antigenically E1 protein
evolves quickly, with correspondingly high rates of posi-
tive selection, as inferred in Tajima’s D test and MCMC anal-
ysis. The genetic diversity of HCV E1 represents these ob-
served changes; meanwhile, the functional implications of
these mutations would shed light on specific roles of virus
evolution and pathogenicity. Further efforts are required
for comprehensive genome analysis that may support ef-
fective control of HCV infection in the region.
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Table 4. Epitope Conservness and Immunogenicity Analysis of Envelop Glycoprotein 1 for Each Genotypea
Genotype Epitope Sequence
Percent Conservancy
Immunogenicity
Median Min Identity, % Maxi Identity, %
1a 192YQVRNSSGLYH202 100 90.00 100.00 0.23502
197SSGLYHVTDC207 0 70.00 80.00 0.11232
230VREGNASRCW239 92.3 50.00 100.00 -0.04545
257QLRRHIDLLV266 100 90.91 100.00 -0.24264
1b 192YQVRNSSGLYH202 69.89 77.78 100.00 0.08
197SSGLYHVTDC207 79.48 72.00 100.00 0.25706
230VREGNASRCW239 10.98 40.00 100.00 -0.169
257QLRRHVDLLV266 95.9 70.00 100.00 0.08034
1g 192YQVRNSSGLYH202 55.6 70.00 90.00 0.12609
197SSGLYHVTDC207 77.8 80.00 90.00 -0.31315
230 VREGNASRCW 239 100 90.91 100.00 0.25706
257QLRRHIDLLV266 77.8 72.73 100.00 0.08034
2a 192VQVRNTSDSYM202 0 30.00 70.00 0.0495
197TSDSYMVTNDC207 0 27.27 81.82 -0.325
230VRTGNKSRCW239 3.2 30.00 90.00 -0.31315
257SLRRHVDLMV266 0 45.45 72.73 0.25706
2c 192 VEVRNTSTSYM202 1.8 40.00 100.00 0.07943
197TSTSYMATNDC207 42.9 60.00 100.00 0.19978
230VRTGNKSRCW 239 76.8 72.73 100.00 -0.246
257SLRRHVDLMV266 33.9 63.64 100.00 -0.16936
3a 192VEVKNNSDTYM202 76.2 54.55 100.00 0.01476
197NSDTYMVDLLV207 90.5 70.00 100.00 0.0495
230VRTGNKSRCW 239 95.2 72.73 100.00 0.06968
257SLRRHVDLMV266 0 40.00 80.00 -0.07535
4a 192VHYRNVSGIYH202 78 40.00 100.00 0.0495
197VSGIYHVTNDC207 3.5 27.27 90.91 0.065
230VRTGNKSRCW239 10.4 30.00 90.00 -0.27415
257SLRRHVDLMV266 54.6 27.27 100.00 0.25706
4d 192VHYRNVSGIYH202 98.36 80.00 100.00 -0.02337
197VSGIYHVTNDC207 14.75 50.00 90.00 -0.14895
230VRTGNKSRCW239 57.38 72.73 90.91 0.18971
257SLRRHVDLMV266 0 36.36 63.64 -0.22298
4l 192VHYRNVSGIYH202 100 90.91 100.00 0.25028
197VSGIYHVTNDC207 100 90.00 100.00 0.0495
230VRTGNKSRCW239 100 90.91 90.91 -0.0248
257SLRRHVDLMV266 0 80.00 80.00 -0.19419
4m 192VHYRNVSGIYH202 75 81.82 90.91 0.25028
197VSGIYHVTNDC207 25 60.00 90.00 0.0495
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230VRTGNKSRCW239 0 81.82 81.82 -0.0248
257SLRRHVDLMV266 0 60.00 80.00 0.25706
4n 192VHYRNVSGIYH202 0 72.73 81.82 -0.05824
197VSGIYHVTNDC207 33.3 81.82 90.91 0.25408
230VRTGNKSRCW239 0 70.00 80.00 -0.21958
257SLRRHVDLMV266 33.3 50.00 100.00 -0.31315
4o 192VHYRNVSGIYH202 0.5 81.82 90.91 0.15514
197VSGIYHVTNDC207 75 81.82 90.91 0.34646
230VRTGNKSRCW239 100 90.00 100.00 0.0495
257SLRRHVDLMV266 25 70.00 90.00 -0.293
4r 192VHYRNVSGIYH202 100 90.91 100.00 0.34646
197VSGIYHVTNDC207 94.1 81.82 100.00 0.06364
230VRTGNKSRCW239 100 90.00 100.00 0.0495
257SLRRHVDLMV266 35.3 70.00 90.00 -0.19419
4u 192VHYRNVSGIYH202 100 100.00 100.00 -0.17642
197VSGIYHVTNDC207 100 90.91 100.00 0.00437
230VRTGNKSRCW239 100 90.00 100.00 0.16386
257SLRRHVDLMV266 25 70.00 100.00 -0.06237
aThe analysis was performed on IEDB online tool (22, 23) to check epitopes conservancy and immunogenicity using consensus reference sequences. Immunogenicity
score more than 0.4 for an epitope is considered good as it can produce strong neutralizing antibodies against HCV.
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Table 5. Comparative Residue Analysis of Envelope Glycoprotein E1 Gene for Important Motifsa
Genotype/Subtype Year Country N-Terminal Domain Motifs
1
Reference 2002 USA 192YQVRNSSGLYH202 197SSGLYHVTNDC207 226CXXC229 230VREGNASRCW239 257QLRRHIDLLV266
1a 2011 KSA ……T…. .T…….. …. …..T…. ……….
2011 IRN ……….. ..…….. …. …..S.K.. ……….
2010 IRN ……….. ..…….. …. …..S.K.. ……….
2008 IRN ……T…. .T…….. …. ………. ……….
2007 IRN ……….. ..…….. …. …..S.K.. ……….
1993 EGP ……….. ..…….. …. …..S.K.. ……….
1b 2011 KSA .EE..V..EF. V..EF….N. …. ………. TI…V…G
2010 IRN .E…A..V.. ..V……. …. ………. TI…V….
2008 IRN .E…A..V.. A..V……. …. ………. TI…V….
2007 IRN FE…A..M.Q A..M.Q….. …. …N.S…. TI…V….
2000 TUN .E…V..A.. V..A……. …. …..Y…. TI…V….
2000 KSA .E…V..A.. V..A……. …. …..T…. TI…V….
1993 EGP .E…V..A.. V..A……. …. …..R.Q.. TI…V….
1g 2011 KSA .KI..V..I.. V..I……. …. …..V…. DV…V….
2002 EGP .EI..V..I.. V..I……. …. ………. DV…V….
1993 EGP .EI..V..I.. V..I……. …. …..V…. DV…V….
2
Reference 2011 CA 192VEVKNNSDTYM202 197NSDTYMATNDC207 226CXXC229 230EREGNNSRCW239 257GLRAHIDIIV266
2a 2011 SA .Q…T.NS.. T.NS..V…. …. .N…T…. …….V..
2009 TUN A….T.Q… T.Q…….. …. .D…T…. …T…L..
2008 TUN …R.T.Q… T.Q…….. …. .KDN.T... …T…L..
2007 TUN …R.T.Q… T.Q…….. …. …..T…. …T…A..
2006 TUN A….T.EL.I T.EL.I….. …. ..KD.E…. …S.V….
2005 TUN .Q…TTTS.. TTTS……. …. .LK..S.F.. …T…T..
2004 TUN …..T.Q… T.Q…V…. …. .LV..K.L.. …T…L..
2003 TUN …..T.Q… T.Q…V…. …. .SVNNV…. …T…L..
2c 2004 TUN …R.T.I… T.I…….. …. ..I..V…. …T…T..
2003 TUN ....T.VL.. T.VL……. …. .QT..V…. …T…T..
2g 2011 KSA ..IR.I.NS.. I.NS……. …. .RI..V…. …….V..
2009 TUN ….NT..S.. NT..S……. …. .QI..V…. ..….A..
2008 TUN …..T.KS.. T.KS……. …. .RN..V…. …….V..
2007 TUN …..T.NS.. T.NS……. …. ..T..V…. ……….
2005 TUN …..T.TS.. T.TS……. …. .KLD.V…. …….V..
2004 TUN …..T..S.. T..S……. …. EQI..I…. …….V..
2003 TUN …..T.EL.. T.EL……. …. ..S..G.W.. …….V..
3
Reference 2012 CA 192LEYRNSSGLYV202 197SSGLYVLTNDC207 226CXXC229 230VRKGNTSQCW239 257SLRSHVDLMV266
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3a 2011 KSA ..W..T….. T………. …. .Q…..M.. .I.G….L.
2016 PAK ..W..T….. T........AR …. .QTG…K.. .I.G….L.
2011 IRN ..W..T….. T………. …. .QD….T.. .V.R….L.
2008 IRN ..W..T….. T………. …. .QD….T.. .I……L.
3b PAK …..T….. T………. …. .PCVT.G.K.. .I.N….L.
4
Reference 2011 UK 192VHYRNVSGIYH202 197VSGIYHVTNDC207 226CXXC229 230VRTGNKSRCW239 257SLRRHVDLMV266
4a 2011 KSA .N…A….. A…..I…. …. …..L…. …S……
2012 EGP IN……… ……….. …. .K…Q…. …S……
2013 EGP IN…A..V.. A..V……. …. ..V..Q.S.. …S……
2006 EGP TN…A..V.. A..V……. …. ………. …S……
2003 EGP TN……… ……….. …. ..S..Q…. …S…..G
2002 EGP TN……… ……I…. …. ..E..Q…. …S……
1993 EGP VN…I..V.. I..V……. …. ..V..Q…. …S……
1993 EGP IN……… ……….. …. .RE..Q…. …S……
4d 2011 KSA YN…S..V.. S..V..V…. …. ..V….T.. ……….
4l 2011 EGP I….A.DV.. A.DV..V…. …. .KV..R.Q.. …K……
4m 2002 EGP I.…A..V.. A..V..V…. …. …..V…. E..H…ML.
1993 EGP A….A..V.. A..V……. …. .K…V…. A……ML.
4n 2011 KSA I.H..S….. S………. …. ..S..V…. ……….
4o 2011 KSA I..H.T….. T………. …. ..V..I…. ……….
2002 EGP I….T….. T………. …. V.E……. …Q…...
4r 2011 YEM E….A….. A………. …. .K…V…. .F……..
2011 KSA E….A….. A………. …. ..T..V…. .F……..
1994 YEM E….A….. A………. …. .K…V…. .F……..
4f 2000 ALG …H.T..V.. T..V……. …. …..R.Q.. .V……..
5
Reference 2011 USA 192VHYRNVSGIYH202 197VSGIYHITNDC207 226CXXC229 230VRKGNKSRCW239 257PLRRHVDLLA266
5a 2009 ALG .P…A..V.. A..V……. …. …D.V…. ….A..Y..
6
Reference 2010 CN 192LTYGNSSGLYH202 197SSGLYHLTNDC207 226CXXC229 230VKVDNQSTCW239 257GFRRHVDLLA266
6a 2011 IRN ……….. ……….. …. ………. ……….
Abbreviations: ALG, Algeria; CA, Canada; CN, China; EGP, Egypt; IRN, Iran; KSA, Kingdom of Saudi Arabia; PAK, Pakistan; TUN, Tunisia; USA, United States of America; YEM,
Yemen.
aSelective isolates from each genotype are presented in this table to represent genotype-specific residue mutations in all genotypes reported from the MENA region.
Only genotype 1i and 4u are not presented due to unavailability of their reference genome in www.hcv.lanl.gov/ database. All motifs are positioned at the whole genome
sequences of HCV. The identical amino acid is shown as “.”
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